ReligenDX is dedicated to advancing the understanding and treatment of neurodevelopmental, neuropsychiatric and neurodegenerative disorders through innovative diagnostic testing. Our comprehensive suite of tests, including FRAT®, MitoSwabTM, MitoSeqTM, and ReliExomeTM, provide valuable insights into the underlying genetic and metabolic factors contributing to neurodevelopmental, neuropsychiatric and neurodegenerative conditions.
Our comprehensive genetic testing services, including Whole Exome and Genome Sequencing, provide valuable insights into your unique genetic makeup. By identifying key genetic variations, we enable healthcare providers to deliver personalized care and targeted interventions, empowering you to take control of your health.
Our cutting-edge CholEffluXTM test analyzes HDL function, providing a comprehensive assessment of cardio vascular risk factors. By identifying impairments in cholesterol efflux capacity, healthcare providers can develop targeted interventions to improve cardio vascular health outcomes.
ReligenDX is committed to advancing cancer diagnostics and personalized treatment strategies. Our state-of-the-art genetic testing solutions, such as sTRA, CA 19-9 and ReliExomeTM, help identify key biomarkers and genetic variations that can lead to targeted therapies and improve patient outcomes.
16%
Children in the United States were diagnosed with a Developmental Disability
1/36
1 in 36 Children in the United States have been identified with ASD
48.5%
American adults that have Heart or Blood Vessel Disease
Our testing directly addresses researched diagnosis of these conditions on a cellular and molecular level. Testing at these levels allows for individualized results and treatments, leading physicians and patients towards optimal personalized health.